Future Pak Proposes Acquisition of Theratechnologies Inc. at Significant Premium
- Future Pak proposes to acquire Theratechnologies for $3.51 to $4.50 per share, totaling up to $255 million.
- Theratechnologies forms a special committee to evaluate the acquisition offers and engage in an open process.
- The acquisition proposal includes $205 million in cash and potential performance-based payments linked to EGRIFTA's success.
Future Pak Proposes Acquisition of Theratechnologies Inc. Amid Strategic Evaluation
In a significant move aimed at acquiring Theratechnologies Inc., Future Pak, LLC submits two formal proposals to purchase all outstanding shares of the biotechnology company. The latest offer presents a price range of $3.51 to $4.50 per share, which translates to a total enterprise value of up to $255 million. This comprehensive proposal includes $205 million in cash at closing and potential contingent value rights (CVR) payments, which could yield an additional $50 million based on the performance of the EGRIFTA franchise. Specifically, these CVRs stipulate that Future Pak would pay 50% of any annual gross profit exceeding $30 million for three years post-acquisition, along with a $10 million milestone payment if cumulative gross profit surpasses $125 million during that timeframe. The offer represents a substantial premium of approximately 164% to 238% over Theratechnologies' recent closing stock price, signaling Future Pak's commitment to enhancing shareholder value.
Nirav Patel, Chief Growth Officer at Future Pak, emphasizes the company's dedication to not only providing significant returns to Theratechnologies' shareholders but also fostering constructive negotiations to reach a mutually beneficial agreement. Despite the attractive nature of these proposals, engagement from Theratechnologies has been limited, raising questions about the company's strategic direction. The acquisition is fully supported by Colbeck Capital Management, ensuring that financing is not a barrier to the proposed deal. Future Pak has also secured the services of Bourne Partners Securities LLC as its financial advisor and Honigman LLP for legal guidance, asserting that an agreement could be finalized within four to six weeks, contingent upon standard due diligence access.
In response to Future Pak's overtures, Theratechnologies announces the establishment of a special committee to further evaluate the potential sale of the company through an open and non-exclusive process. This committee, comprising independent and disinterested directors, will make recommendations to the full Board of Directors. Theratechnologies has engaged Barclays and Raymond James as financial advisers in this evaluation process, although the company has indicated that it will limit updates to what is required under applicable securities laws. This development signals a pivotal moment for Theratechnologies as it navigates the complexities of a potential acquisition while maintaining its strategic objectives in the competitive biotechnology landscape.
In a broader context, the financial markets are bracing for significant economic data releases, including producer prices and Consumer Price Index (CPI) figures across multiple countries. Meanwhile, earnings reports from various companies, including Abbott Laboratories and Alcoa Corp, are on the horizon, reflecting a busy period for corporate financial disclosures. As Theratechnologies assesses its options, the outcomes of these evaluations and market conditions will play a crucial role in shaping the company's future trajectory.